BIO3 Share Price

Open 17.17 Change Price %
High 17.41 1 Day 0.21 1.22
Low 17.10 1 Week 0.03 0.17
Close 17.39 1 Month 2.25 14.86
Volume 26262 1 Year 4.98 40.13
52 Week High 17.84
52 Week Low 12.02
BIO3 Important Levels
Resistance 2 17.68
Resistance 1 17.56
Pivot 17.30
Support 1 17.22
Support 2 17.10
ETR Germany Most Active Stocks
DTE 16.30 2.77%
DTE 16.30 2.77%
DTE 16.30 2.77%
DTE 16.30 2.77%
DTE 16.30 2.77%
EOAN 7.15 1.27%
EOAN 7.15 1.27%
CBK 7.41 0.00%
CBK 7.41 0.00%
DBK 18.44 1.32%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
E8X 0.42 23.53%
I7N 1.16 17.17%
SZZ 9.27 16.60%
5M71 39.00 13.70%
ZSB 0.12 9.09%
P4Q 0.26 8.33%
R3Q 0.15 7.14%
BEO 3.38 6.96%
PS4 3.10 6.53%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
SMK 0.05 -16.67%
NK2A 0.22 -15.38%
D5I 0.14 -6.67%
PV3 1.51 -6.21%
MF6 4.20 -5.19%
More..

Biotest AG (ETR: BIO3)

BIO3 Technical Analysis 5
As on 20th Feb 2017 BIO3 Share Price closed @ 17.39 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 14.12 & Strong Buy for SHORT-TERM with Stoploss of 14.75 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO3 Target for February
1st Target up-side 17.71
2nd Target up-side 18.81
3rd Target up-side 19.91
1st Target down-side 14.57
2nd Target down-side 13.47
3rd Target down-side 12.37
BIO3 Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO3 Address
BIO3
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO3 Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO3 ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO3 Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.